You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

16 Results
Guidelines and Advice
Status: Current
ID: GL-C50-24
Version: 3
Jan 2024
Guidelines and Advice
Status: Current
ID: GL-C50-32
Jan 2021
Drug
Other Name(s): Ibrance™
May 2021
Regimen
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Jan 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant, Curative, Palliative
Aug 2021
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Jun 2021
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Jun 2021
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Endocrine, 
Gastrointestinal, 
Genitourinary, 
Gynecologic, 
Head and Neck, 
Hematologic, 
Lung, 
Sarcoma, 
Skin, 
Unknown Primary
Intent: Supportive Care, Palliative
Jan 2024
Guidelines and Advice
Status: Current
Version: 2
May 2021
Drug
Other Name(s): Folotyn®
Dec 2021

Pages